Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:12603 |
Name | acute leukemia |
Definition | A lymphoid leukemia that occurs when a hematopoietic stem cell undergoes malignant transformation into a primitive, undifferentiated cell with abnormal longevity producing large numbers of white blood cells to be produced and enter the blood stream. |
Source | DiseaseOntology.org |
Alt Ids | DOID:12621 |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia acute leukemia |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
TP53 wild-type | SAR405838 | acute leukemia | sensitive | detail... |
KMT2A rearrange | Pinometostat | acute leukemia | predicted - sensitive | detail... |
KMT2A rearrange | Revumenib | acute leukemia | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00602693 | Phase I | Sirolimus Allopurinol + Cyclophosphamide + Fludarabine | T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer | Completed | USA | 0 |
NCT00990249 | Phase II | anti-thymocyte globulin + Busulfan + Clofarabine | Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation | Completed | USA | 0 |
NCT01028716 | Phase II | Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Terminated | USA | 0 |
NCT01822509 | Phase I | Ipilimumab + Nivolumab | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | Completed | USA | 0 |
NCT02115295 | Phase II | Cladribine + Cytarabine + Idarubicin Midostaurin | Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML) | Recruiting | USA | 0 |
NCT02135874 | Phase II | Clofarabine + Cytarabine + Dexamethasone + Idarubicin + Sorafenib + Vincristine Sulfate Clofarabine + Cytarabine + Dexamethasone + Idarubicin + Rituximab + Vincristine Sulfate Clofarabine + Cytarabine + Dexamethasone + Idarubicin + Vincristine Sulfate | Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia | Completed | USA | 0 |
NCT02141828 | Phase I | Pinometostat | A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene | Completed | USA | CAN | 0 |
NCT02208037 | Phase II | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | Completed | USA | 0 | |
NCT02212561 | Phase Ib/II | Selinexor Cytarabine Cytarabine + Dexamethasone + Methotrexate Fludarabine | Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome | Completed | USA | 0 |
NCT02225574 | Phase Ib/II | Binimetinib + Nilotinib | An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T) | Terminated | USA | 0 |
NCT02270788 | Phase I | Cytarabine + Leucovorin + Methotrexate Crenolanib + Sorafenib | Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies | Completed | USA | 0 |
NCT02345382 | Phase I | BAY1143572 | Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia | Completed | USA | DEU | 0 |
NCT02390752 | Phase Ib/II | Pexidartinib | PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) | Recruiting | USA | 0 |
NCT02392572 | Phase Ib/II | ONC201 | ONC201 in Relapsed/Refractory Acute Leukemias and High-risk Myelodysplastic Syndromes (HR-MDS) | Recruiting | USA | 0 |
NCT02484261 | Phase I | Bortezomib + Pravastatin | Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children | Terminated | USA | 0 |
NCT02529813 | Phase I | Cyclophosphamide + Fludarabine + Tisagenlecleucel | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | Completed | USA | 0 |
NCT02543879 | Phase I | FT-1101 Azacitidine + FT-1101 | Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies | Completed | USA | 0 |
NCT02551718 | Phase I | Bosutinib Irinotecan Romidepsin Busulfan Melphalan Nilotinib Crizotinib Cytarabine Mitoxantrone Dasatinib Pazopanib Paclitaxel Clofarabine Hydroxyurea Tretinoin Carfilzomib Nelarabine Bexarotene Pentostatin Everolimus Cabozantinib Mercaptopurine Methotrexate Cladribine Thioguanine Daunorubicin Ponatinib Etoposide Afatinib Gefitinib Gemcitabine Regorafenib Arsenic trioxide Trametinib Imatinib Erlotinib Dabrafenib Decitabine Axitinib Azacitidine Ruxolitinib Fludarabine Lapatinib Ceritinib Sirolimus Sorafenib Lomustine Sunitinib Cabazitaxel Temsirolimus Topotecan Bortezomib Pralatrexate | High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia | Completed | USA | 0 |
NCT02722668 | Phase II | Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | Active, not recruiting | USA | 0 |
NCT02727803 | Phase II | anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells | Personalized NK Cell Therapy in CBT | Recruiting | USA | 0 |
NCT02793544 | Phase II | Cyclophosphamide Busulfan Sirolimus Mycophenolate mofetil Mesna Fludarabine | HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide | Completed | USA | 0 |
NCT02828358 | Phase II | Cytarabine + Hydrocortisone + Leucovorin + Mercaptopurine + Pegaspargase Cyclophosphamide + Cytarabine + Hydrocortisone + Mercaptopurine + Methotrexate Cytarabine + Hydrocortisone + Mercaptopurine + Methotrexate Azacitidine Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Pegaspargase + Thioguanine + Vincristine sulfate liposome Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Methotrexate + Pegaspargase + Prednisolone + Vincristine Sulfate Mercaptopurine + Methotrexate Cyclophosphamide + Cytarabine + Thioguanine | Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement | Active, not recruiting | USA | CAN | AUS | 1 |
NCT02879643 | Phase I | Dexamethasone + Methotrexate + Pegaspargase + Vincristine sulfate liposome Dexamethasone + Mercaptopurine + Methotrexate + Vincristine sulfate liposome Dexamethasone + Methotrexate + Mitoxantrone + Pegaspargase + Vincristine sulfate liposome | Vincristine Sulfate Liposome Injection (Marqibo) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL | Unknown status | USA | CAN | AUS | 0 |
NCT02879695 | Phase I | Blinatumomab + Ipilimumab + Nivolumab | Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia | Active, not recruiting | USA | 0 |
NCT03267186 | Phase II | Ibrutinib | Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant | Completed | USA | 0 |
NCT03386513 | Phase Ib/II | IMGN632 | Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | 0 |
NCT03404193 | Phase II | Decitabine + Venetoclax | Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-risk Myelodysplastic Syndrome | Active, not recruiting | USA | 0 |
NCT03483324 | Phase I | AB-110 | Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation | Completed | USA | 0 |
NCT03519984 | Phase I | sEphB4-HSA + Vincristine sulfate liposome Cytarabine + sEphB4-HSA | EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia | Terminated | USA | 0 |
NCT03739606 | Phase II | Flotetuzumab | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | Withdrawn | 0 | |
NCT03826992 | Phase I | CPX-351 + Venetoclax | Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia | Recruiting | USA | 0 |
NCT03834961 | Phase II | Larotrectinib | Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia | Active, not recruiting | USA | CAN | 0 |
NCT03959085 | Phase III | Dexamethasone + Doxorubicin + Methotrexate + Pegaspargase + Vincristine Sulfate Cyclophosphamide + Cytarabine + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine Sulfate Leucovorin + Mercaptopurine + Methotrexate + Vincristine Sulfate Inotuzumab ozogamicin Cytarabine + Daunorubicin + Dexamethasone + Methotrexate + Pegaspargase + Vincristine Sulfate Cytarabine + Daunorubicin + Methotrexate + Pegaspargase + Prednisolone + Vincristine Sulfate Cyclophosphamide + Cytarabine + Methotrexate + Pegaspargase + Thioguanine + Vincristine Sulfate Inotuzumab ozogamicin + Methotrexate Methotrexate + Pegaspargase + Vincristine Sulfate Mercaptopurine + Methotrexate + Prednisolone + Vincristine Sulfate | Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | Recruiting | USA | NZL | CAN | AUS | 1 |
NCT04047641 | Phase II | Quizartinib Cladribine + Cytarabine + Idarubicin + Quizartinib | Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT04681105 | Phase I | Acetaminophen + Dexamethasone + Diphenhydramine + Flotetuzumab + Ranitidine Dexamethasone + Diphenhydramine + Flotetuzumab + Ibuprofen + Ranitidine | Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies | Active, not recruiting | USA | 0 |
NCT04811560 | Phase I | JNJ-75276617 | A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia | Recruiting | USA | GBR | FRA | ESP | AUS | 1 |
NCT04898894 | Phase I | Cytarabine + Filgrastim + Fludarabine + Methotrexate + Selinexor + Venetoclax | Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT04988555 | Phase Ib/II | DSP-5336 | A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation | Recruiting | USA | ITA | FRA | ESP | CAN | BEL | 4 |
NCT05005299 | Phase I | Cyclophosphamide + Fludarabine + Venetoclax | Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation (VICTORY) | Recruiting | AUS | 0 |
NCT05153330 | Phase I | BMF-219 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL With KMT2A/ MLL1r, NPM1 and Other Mutations | Recruiting | USA | NLD | ITA | GRC | ESP | 0 |
NCT05521087 | Phase I | Cytarabine + Dexamethasone + Fludarabine + JNJ-75276617 + Pegaspargase + Vincristine Sulfate | A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias | Withdrawn | USA | 0 |
NCT05823571 | Phase I | Itacitinib | Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | Recruiting | USA | 0 |
NCT05918913 | Expanded access | Revumenib | Expanded Access Program for SNDX-5613 | Available | USA | 0 |
NCT06229912 | Phase II | Revumenib | A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes | Recruiting | USA | 0 |
NCT06466395 | Phase I | Cyclophosphamide + Dexamethasone + Doxorubicin + Venetoclax + Vincristine Sulfate | A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias | Not yet recruiting | USA | 0 |
NCT06575296 | Phase I | Revumenib | Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant | Not yet recruiting | USA | 0 |